tbuckley/cabot-search huggingface dataset:
Abstract 2562: EGCG targeting of adipogenesis reveals a STAT3-mediated paracrine oncogenic control of triple-negative breast cancer cell invasive phenotype
Authors: Narjara Gonzalez Suarez, Sahily Rodriguez Torres, Borhane Annabi
Journal: Cancer Research (2021)

Abstract Background: Obese subjects have an increased risk of developing triple-negative breast cancer (TNBC), in part associated with the chronic low-grade inflammation state. On the other hand, epidemiological data indicates that increased consumption of polyphenol-rich fruits and vegetables plays a key role in reducing incidence of some cancers. Objectives: Here, we tested whether green tea-derived epigallocatechin-3-gallate (EGCG) could alter adipogenesis involved in the maturation of pre-adipocytes, and how this impacts the paracrine regulation of the mature adipocytes secretome on the TNBC invasive phenotype. Methods: Differentiation was performed and conditioned media (CM) from preadipocytes and mature adipocytes harvested. Human TNBC-derived MDA-MB-231 real-time cell migration was performed using the exCELLigence system. Differential gene arrays and RT-qPCR were used to assess gene expression levels. Western blotting was used to assess protein expression levels. In vitro vasculogenic mimicry (VM) was assessed with Matrigel. Results: EGCG was found to inhibit the induction of numerous key adipogenic biomarkers, including lipoprotein lipase, adiponectin, leptin, fatty acid synthase, and fatty acid binding protein 4. Increased MDA-MB-231 chemotaxis and VM were found in response to mature adipocytes secretome, and this was correlated with the induction of the STAT3 signaling pathway. This invasive phenotype was prevented by EGCG, JAK/STAT inhibitors Tofacitinib and AG490, as well as upon STAT3 gene silencing. Conclusion: Adipocytes secretome plays a key role in the paracrine regulation of TNBC cells invasive phenotype. Dietary catechin-mediated interventions may, in part through the inhibition of adipogenesis and modulation of adipocytes secretome, prevent the onset of an obesogenic environment that favors TNBC development. Citation Format: Narjara Gonzalez Suarez, Sahily Rodriguez Torres, Borhane Annabi. EGCG targeting of adipogenesis reveals a STAT3-mediated paracrine oncogenic control of triple-negative breast cancer cell invasive phenotype [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2562.
Abstract 312: Targeted NanoSpheres (TNS)
Authors: HyungGyoo Kang, Jon Nagy, Bryon Upton, Racheal Upton, Timothy Triche, Timothy Triche
Journal: Cancer Research (2021)

Abstract The tumor-targeted, nanoparticle delivery technology has shown the possibility of increasing the delivered dose of virtually any small therapeutics to tumor cells while limiting the drug uptake by normal tissues, thereby greatly increasing the effective MTD. By refining the early formulations and after extensive testing, we developed a novel targeted liposomal nanoparticle, Targeted NanoSpheres (TNS). We showed this novel nano-formulated platform can overcome many deficiencies of conventional nanoparticles and therefore has enhanced potential as an effective delivery vehicle for virtually any type of cancer for which a suitable tumor cell surface antigen is present. We have developedNV103, a first-in-class anti-CD99 TNS (CD99-TNS/Irinotecan), for the treatment of Ewing Sarcoma (EWS), a highly lethal pediatric and young adult bone and soft tissue tumor driven by a fusion protein, typically EWS/FLI1 in over 85% of cases. Cancer cells have the ability to develop resistance to the chemotherapy. Our present salvage/rescue study with NV103 showed that NV103 can overcome irinotecan resistance of Ewing tumor with simple change of dose schedule (dose intensification), not increasing the dose. The results from our salvage/rescue studies with NV103 suggested that successful dose intensification schedules with NV103 could be used to treat relapsed or resistant patients in future clinical trials. Furthermore, Targeted Nanosphere (TNS) can be used to overcome drug resistance of various cancers.This platform is also being investigated for other types of cancer that either express CD99, or other tumor antigens like GD2 and B7-H3. Citation Format: HyungGyoo Kang, Jon Nagy, Bryon Upton, Racheal Upton, Timothy Triche, Timothy Triche. Targeted NanoSpheres (TNS) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 312.
Abstract 9966: Sequential Stimulation and Inhibition of Lysophosphatidic Acid Receptor 4 are Critical for Cardiac Differentiation and Repair
Authors: Hyun-Jai Cho, Choon-Soo Lee, Jin-Woo Lee, Hyo-Soo Kim
Journal: Circulation (2019)

Background: The clinical application of cell therapy to repair the damaged heart needs to understand the precise differentiation process of stem cells and the characteristics of cardiac progenitor ...
The switching phenotype and intratumor plasticity in carcinoma of the bladder: A mono-institutional analysis of 211 muscle-invasive carcinoma patients with clinical considerations for therapy
Authors: P. Colombo, P.A. Zucali, C. De Carlo, G.M. Elefante, R. Hurle, M. Lazzeri, F. D’Antonio, M. Cieri, L. Giordano, M. Perrino, V. Belsito, A. Santoro, G. Guazzoni, L.M. Terracciano
Journal: European Urology (2021)
Chemotherapy induces canalization of cell state in childhood B-cell precursor acute lymphoblastic leukemia
Authors: Virginia A. Turati, José Afonso Guerra-Assunção, Nicola E. Potter, Rajeev Gupta, Simone Ecker, Agne Daneviciute, Maxime Tarabichi, Amy P. Webster, Chuling Ding, Gillian May, Chela James, John Brown, Lucia Conde, Lisa J. Russell, Phil Ancliff, Sarah Inglott, Giovanni Cazzaniga, Andrea Biondi, Georgina W. Hall, Mark Lynch, Mike Hubank, Iain Macaulay, Stephan Beck, Peter Van Loo, Sten E. Jacobsen, Mel Greaves, Javier Herrero, Tariq Enver
Journal: Nature Cancer (2021)
Abstract 2646: Implication of different anti-angiogenic treatments on in vitro vascular tube formation in triple negative inflammatory breast cancer cell lines
Authors: Sara Caceres, Angela Alonso-Diez, Belen Crespo, Eduardo ESpinosa, Beatriz Madaruiaga, Gema Silvan, Maria J. Illera, Juan Carlos Illera
Journal: Cancer Research (2021)

Abstract Introduction: Inflammatory breast cancer (IBC) is the most aggressive breast cancer in women and female dogs (IMC, Inflammatory mammary cancer) with a poor prognosis. Both IBC and IMC are highly angiogenic, lymphangiogenic and lymphangioinvasive. The aim of this study was to evaluate the effect of different anti-angiogenic treatments in the in vitro formation of vascular-like structures as well as cell secretion of different angiogenic and lymphangiogenic factors (VEGFA, VEGFC, VEGFD) and interleukin-8 (IL-8) in culture media. Material and Methods: For in vitro tube formation assay, culture human SUM149 cells and canine IPC-366 cells were divided into a control group, treated with DMSO, and 4 experimental groups treated with 1.5 μM of VEGF, SU5416 (anti-VEGFR, VEGF B20-4.1.1 (anti-VEGF) and celecoxib (NSAID), respectively, for 4 h at 37ºC in 5% CO2 conditions. Images were taken every 2 hours. Incomplete networks were excluded, and vessel-like tube structures were counted using the Image J Angiogenesis Analyzer software. Data were represented as average percentage relative to control ± SD. Results: VEGF and celecoxib treatment significantly augmented the formation of vascular-like tube structures respect to control group in both cell lines. However, VEGF B20-4.1.1 and SU5416 decreased the formation of vascular-like tube structures but not significantly. Conditionate media of IPC-366 and SUM149-treated cells with VEGF had significantly decreased VEGFA levels. In contrast, celecoxib treatment, reduced VEGFD levels and increased VEGFC in both cell lines. VEGF B20-4.1.1 addition increased VEGFA levels in culture media and SU5416 significantly diminished VEGFD concentrations. No significant differences in IL-8 levels were found for any treatment. Conclusions: Increased VEGFC levels after celecoxib treatment suggest a switch from a proangiogenic state toward a lymphangiogenic state. Neutralization of VEGF by VEGF B20-4.1.1 enhances the secretion of VEGFA and VEGFC by tumor cells inhibiting angiogenesis and lymphangenesis. Citation Format: Sara Caceres, Angela Alonso-Diez, Belen Crespo, Eduardo ESpinosa, Beatriz Madaruiaga, Gema Silvan, Maria J. Illera, Juan Carlos Illera. Implication of different anti-angiogenic treatments on in vitro vascular tube formation in triple negative inflammatory breast cancer cell lines [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2646.
Artificial Intelligence for Augmenting Perioperative Surgical Decision-Making—Are We There Yet?
Authors: Amin Madani, Liane S. Feldman
Journal: JAMA Surgery (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Adding Beta-2 Microglobulin for Better Prognostication of Primary Central Nervous System Lymphoma
Authors: Jaewon Hyung, Jung Yong Hong, Dok Hyun Yoon, Kyoungmin Lee, Shin Kim, Chan-Sik Park, Jooryung Huh, Jin-Sook Ryu, Cheolwon Suh
Journal: Blood (2017)
Robot-assisted simple prostatectomy versus HOLEP, multicenter comparative outcomes
Authors: A.M. Bove, A. Brassetti, U. Anceschi, G. Tuderti, L. Misuraca, M. Ferriero, R. Mastroianni, R. Lombardo, C. De Nunzio, M. Gallucci, G. Simone
Journal: European Urology (2021)
Abstract 1777: Examining dendritic cell heterogeneity in the tumor microenvironment
Authors: Tsun Ki Jerrick To, Samir Devalajara, Ian W. Folket, Malay Haldar
Journal: Cancer Research (2021)

Abstract Dendritic cells (DCs) are key regulators of anti-tumor immunity with critical roles in priming and stimulating anti-tumor T cells. DCs have heterogeneous phenotype, ontogeny, activation status, and function. However, the distribution of DC subsets within solid tumors remains unclear. Moreover, the study of intratumoral DCs is hampered by their rarity and difficulties associated with distinguishing DCs from other similar cell types in the tumor microenvironment. Using genetically engineered DC reporter mice (ZBTB46-GFP), we performed single-cell RNA-sequencing (scRNA-seq) on DCs from tumors and normal tissue as an unbiased approach for examining DC heterogeneity. Within our scRNA-seq analysis, we identified the major ontological DC subsets (cDC1s and cDC2s) along with two activated DC subsets: one that expressed a migratory signature (mDC) and the other that expressed an interferon-signaling signature (IFN-DC). By comparing DCs in different tumor models and healthy lung tissue, we found that mDCs were present in both tumor and normal tissue, while IFN-DCs were specific to tumors. IFN-DCs were Sca-1high and were selectively enriched for key anti-tumor interferon-stimulated genes such as Cxcl9 and Cxcl10. Additionally, IFN-DCs were further separated into a type I IFN-enriched subcluster (IFN-DC1) and a type II IFN-enriched subcluster (IFN-DC2). IFN-DC2s were lost in tumors of cDC1-deficient Batf3-KO mice as revealed by scRNA-seq of tumor DCs in Batf3-KO mice. Further experiments suggested that this loss of IFN-DC2 was a cell-extrinsic effect due to the dramatic decrease in IFNy in the tumor microenvironment. Specifically, the decrease in IFNy was associated with the absence of cDC1-primed IFNy-producing CD8 T cells in Batf3-KO tumors. In summary, our analysis of tumor DCs using scRNA-seq and DC reporter mice reveals heterogeneous activated DC subsets, including DCs enriched for distinct type I and type II IFN signaling. Further elucidation of the functional relevance of each subset to the tumor immune response can enable more specific targeting of DCs for cancer immunotherapy. Citation Format: Tsun Ki Jerrick To, Samir Devalajara, Ian W. Folket, Malay Haldar. Examining dendritic cell heterogeneity in the tumor microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 1777.
Inclusion of Underrepresented Groups in Preclinical Alzheimer Disease Trials—Opportunities Abound
Authors: Jennifer J. Manly, Andrea Gilmore-Bykovskyi, Kacie D. Deters
Journal: JAMA Network Open (2021)

Rema Raman, PhD; Yakeel T. Quiroz, PhD; Oliver Langford, MS; Jiyoon Choi, MS; Marina Ritchie, MA; Morgan Baumgartner; Dorene Rentz, PsyD; Neelum T. Aggarwal, MD; Paul Aisen, MD; Reisa Sperling, MD; Joshua D. Grill, PhD
Factors Associated With Symptoms of Depression and Anxiety Among Women Experiencing Homelessness and Unstable Housing During the COVID-19 Pandemic
Authors: Elise D. Riley, Samantha E. Dilworth, Derek D. Satre, Michael J. Silverberg, Torsten B. Neilands, Christina Mangurian, Sheri D. Weiser
Journal: JAMA Network Open (2021)

The prevalence of depression among individuals in the US has increased 300% during the COVID-19 pandemic, with a greater burden of illness in individuals with lower incomes.1 With the goal of informing adaptation of services for socioeconomically marginalized individuals, we surveyed mental health symptoms and social challenges experienced during the COVID-19 pandemic among women experiencing homelessness and unstable housing (HUH). Extrapolating from the available evidence,2,3 there are approximately 440 000 women experiencing HUH in the US.
Colorectal cancer screening offering colonoscopy and FIT vs. colonoscopy alone improved participation
Authors: Thomas F. Imperiale
Journal: Annals of Internal Medicine (2021)

Source Citation Pilonis ND, Bugajski M, Wieszczy P, et al. Participation in competing strategies for colorectal cancer screening: a randomized health services study (PICCOLINO study). Gastroenterology. 2021;160:1097-105. 33307024
Abstract 2574: Collagen density and obesity promote mammary gland inflammation
Authors: Abbey E. Williams, Abbey E. Williams, Erica Hoffman, Julia Warren, Suzanne Ponik, Lisa M. Arendt
Journal: Cancer Research (2021)

Abstract Recent epidemiological studies suggest that the risk factors of breast density and obesity together increase breast cancer risk in premenopausal women, and these women have a worsened prognosis following breast cancer diagnosis. Although the underlying causes of increased risk associated with dense breasts and obesity have individually been explored, little is known about how these underlying risk factors interact together to enhance breast cancer risk. To model breast density, we used heterozygous Col1a1tmjae mice, that have a mutation that limits collagen degradation, leading to increased mammary collagen deposition. Heterozygous (het) mice or wild type (wt) litter mates were fed either a control diet (CD) or a high fat diet (HFD) to induce obesity. We quantified F4/80-positive macrophages within mammary glands using immunohistochemistry. We observed significantly increased numbers of macrophages in mammary glands of CD/het, HFD/wt and HFD/het mice compared to CD/wt mice. We observed significantly enhanced picrosirius red stained collagen surrounding mammary ducts from CD/het, HFD/wt, and HFD/het mice compared to those from CD/wt mice. Notably, HFD/het mice had significantly more collagen surrounding ducts than in mammary glands from CD/het mice. These results may suggest that obesity enhances collagen deposition and macrophage-driven inflammation within dense breast tissue in the mammary glands of non-tumor-bearing mice. Citation Format: Abbey E. Williams, Abbey E. Williams, Erica Hoffman, Julia Warren, Suzanne Ponik, Lisa M. Arendt. Collagen density and obesity promote mammary gland inflammation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2574.
Abstract CT156: Radiologic scoring method to define the therapeutic response and surgical candidacy
Authors: Syed Rahmanuddin, Daniel Von Hoff, Derek Cridebring, Jordyn Brase, Yuman Fong, Pejman Motarjem, Ron Korn, Kevin Choong, William Boswell, Erkut Borazanci
Journal: Cancer Research (2021)

Abstract Purpose: The purpose of this study is to define the best CT perfusion analytical method for the surgical candidacy of pancreatic cancer patients in Neo-Adjuvant treated clinical trial population. Experimental Design: Study was designed to assess tumor perfusion status. This prospective study involved 24 adult patients with pancreatic adenocarcinoma (PDAC). Inclusion criteria included, patients with histologically or cytologically confirmed resectable, borderline resectable, or locally advanced (unresectable) PDAC. All patients received neoadjuvant therapy (paricalcitol, paclitaxel protein bound, cisplatin and gemcitabine) for up to 6 months Multi-phase CT was performed for most patients on a GE scanner using a standard pancreatic cancer protocol including a pre-injection phase, arterial phase, and porto-venous phase. The iodinated contrast agent Isovue 370 was dosed at 150 cc + 40 cc saline, and injected at a rate of 5 cc/sec into the antecubital vein. Volumetric analysis of images from 24 patients was conducted using 3D imaging software and perfusion scoring assessment was done on each case using 2D and 3D methodology. Regions of interest were drawn to define the volumetric tumor quantification. This work looked at the difference in density between arterial and venous phases, using the Marley equation. This data was then used to assess treatment response and ultimately whether or not a patient would be a surgical candidate. This surgical candidacy of these patients was defined by the “R” score. Results: The R score defines the number of vessels with tumor involvement. Each vessel that had any amount of tumor involvement was scored with a 1. Any patient with a score of 6 or higher was deemed not eligible for surgery while a score of 5 or less was eligible for surgery. 3D Tumor volumetric assessments were performed for the assessment of the treatment response that linked directly with the tumor perfusion.Conclusion: CT vessel perfusion using the R score method could be helpful to define the surgical candidacy of pancreatic cancer patients along with 3D tumor volumetric quantification. Citation Format: Syed Rahmanuddin, Daniel Von Hoff, Derek Cridebring, Jordyn Brase, Yuman Fong, Pejman Motarjem, Ron Korn, Kevin Choong, William Boswell, Erkut Borazanci. Radiologic scoring method to define the therapeutic response and surgical candidacy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT156.
Efficacy, acceptability, and safety of muscle relaxants for adults with non-specific low back pain: systematic review and meta-analysis
Authors: Aidan G Cashin, Thiago Folly, Matthew K Bagg, Michael A Wewege, Matthew D Jones, Michael C Ferraro, Hayley B Leake, Rodrigo R N Rizzo, Siobhan M Schabrun, Sylvia M Gustin, Richard Day, Christopher M Williams, James H McAuley
Journal: BMJ (2021)

Abstract Objective To investigate the efficacy, acceptability, and safety of muscle relaxants for low back pain. Design Systematic review and meta-analysis of randomised controlled trials. Data sources Medline, Embase, CINAHL, CENTRAL, ClinicalTrials.gov, clinicialtrialsregister.eu, and WHO ICTRP from inception to 23 February 2021. Eligibility criteria for study selection Randomised controlled trials of muscle relaxants compared with placebo, usual care, waiting list, or no treatment in adults (≥18 years) reporting non-specific low back pain. Data extraction and synthesis Two reviewers independently identified studies, extracted data, and assessed the risk of bias and certainty of the evidence using the Cochrane risk-of-bias tool and Grading of Recommendations, Assessment, Development and Evaluations, respectively. Random effects meta-analytical models through restricted maximum likelihood estimation were used to estimate pooled effects and corresponding 95% confidence intervals. Outcomes included pain intensity (measured on a 0-100 point scale), disability (0-100 point scale), acceptability (discontinuation of the drug for any reason during treatment), and safety (adverse events, serious adverse events, and number of participants who withdrew from the trial because of an adverse event). Results 49 trials were included in the review, of which 31, sampling 6505 participants, were quantitatively analysed. For acute low back pain, very low certainty evidence showed that at two weeks or less non-benzodiazepine antispasmodics were associated with a reduction in pain intensity compared with control (mean difference −7.7, 95% confidence interval−12.1 to−3.3) but not a reduction in disability (−3.3, −7.3 to 0.7). Low and very low certainty evidence showed that non-benzodiazepine antispasmodics might increase the risk of an adverse event (relative risk 1.6, 1.2 to 2.0) and might have little to no effect on acceptability (0.8, 0.6 to 1.1) compared with control for acute low back pain, respectively. The number of trials investigating other muscle relaxants and different durations of low back pain were small and the certainty of evidence was reduced because most trials were at high risk of bias. Conclusions Considerable uncertainty exists about the clinical efficacy and safety of muscle relaxants. Very low and low certainty evidence shows that non-benzodiazepine antispasmodics might provide small but not clinically important reductions in pain intensity at or before two weeks and might increase the risk of an adverse event in acute low back pain, respectively. Large, high quality, placebo controlled trials are urgently needed to resolve uncertainty. Systematic review registration PROSPERO CRD42019126820 and Open Science Framework https://osf.io/mu2f5/ .
Prostate vascularity and surgical blood loss during Holmium Laser Enucleation of the Prostate (HoLEP): Short-term pretreatment with dutasteride
Authors: G.M. Busetto, F. Del Giudice, M. Maggi, U. Falagario, E. De Berardinis, A. Sciarra, L. Cormio, G. Carrieri, A. Porreca
Journal: European Urology (2021)